InterVenn

formerly InterVenn BioSciences

InterVenn Biosciences | Clinical Glycoproteomics

South San Francisco, United States · Founded 2017 · $253.8M raised

Employees
51–200
Founded
2017
Business Model
B2B
Total Funding
$253.8M
Last Round
$201.0M Series CAug 2021
Rounds
4

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

InterVenn Biosciences pioneers AI- and ML-powered glycoproteomic analysis through its GlycoVision platform, enabling high-throughput biomarker discovery from blood samples. Co-founded in 2017 by Nobel Laureate Carolyn Bertozzi, Dr. Carlito Lebrilla, and Aldo Carrascoso, the company serves biopharma partners and clinicians with diagnostic applications including GlycoKnow Ovarian for ovarian cancer detection.

Summary

InterVenn is an Artificial Intelligence company based in South San Francisco, United States, founded in 2017. It has raised $253.8M in total across 4 rounds, most recently a $201.0M Series C round in Aug 2021. Investors include Amplify Partners, Genoa Ventures and Anzu Partners.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series CSeries CAug 2021
$201.0M

Sign up to see all 4 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Devoted Health

Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...

Waltham, United States1001–5000Artificial Intelligence, Healthcare
Series FTotal funding$3.8BJan 2026
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Verily Life Sciences

Verily builds AI-native precision health platforms that help healthcare organizations harmonize d...

Dallas, United States1001–5000Artificial Intelligence, Healthcare
Corporate RoundTotal funding$3.0BMar 2026
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

InterVenn on Indexed.vc
<a href="https://indexed.vc/companies/intervenn"><img src="https://indexed.vc/api/badge/company/intervenn" alt="InterVenn on Indexed.vc" width="260" height="76" /></a>